{"filing":{"accession_number":"0001645113-26-000056","cik":"0001645113","ticker":"NVCR","company_name":"NovoCure Ltd","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"nvcr-20260630.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000056/nvcr-20260630.htm"},"events":[{"id":14825,"run_id":13218,"accession_number":"0001645113-26-000056","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"NovoCure announced that Optune Pax® received CE Mark approval for treating locally advanced pancreatic cancer, supported by Phase 3 PANOVA-3 trial data showing statistically significant improvement in overall survival and pain progression delay. This is a material regulatory milestone and product approval event that is operational/commercial in nature—the company is expanding market access for a key product—but does not fit the specific categories of earnings release, M\u0026A, impairment, or other defined event types. The disclosure is material because regulatory approvals and product launches directly affect revenue prospects and competitive positioning.","company_name":"NovoCure Ltd","ticker":"NVCR","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12377,"accession_number":"0001645113-26-000056","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"NovoCure announced that Optune Pax® received CE Mark approval for treating locally advanced pancreatic cancer, supported by Phase 3 PANOVA-3 trial data showing statistically significant improvement in overall survival and pain progression delay. This is a material regulatory milestone and product approval event that is operational/commercial in nature—the company is expanding market access for a key product—but does not fit the specific categories of earnings release, M\u0026A, impairment, or other defined event types. The disclosure is material because regulatory approvals and product launches directly affect revenue prospects and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T11:01:41.931926+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12377,"accession_number":"0001645113-26-000056","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"NovoCure announced that Optune Pax® received CE Mark approval for treating locally advanced pancreatic cancer, supported by Phase 3 PANOVA-3 trial data showing statistically significant improvement in overall survival and pain progression delay. This is a material regulatory milestone and product approval event that is operational/commercial in nature—the company is expanding market access for a key product—but does not fit the specific categories of earnings release, M\u0026A, impairment, or other defined event types. The disclosure is material because regulatory approvals and product launches directly affect revenue prospects and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T11:01:41.931926+00:00","company_name":"NovoCure Ltd","ticker":"NVCR","filing_date":"2026-06-30"}]}